Mylan has one of the industry’s largest
and most diverse global portfolios: including 20 biosimilars and insulin
analogs.
Our portfolio includes many of the top
biologics globally and focuses on the areas of oncology, immunology,
endocrinology and ophthalmology.
Every biosimilar we add to our portfolio
may help provide more patients in more countries with the treatment they need.
We are committed to continuing to invest in biosimilars.
|
